What is Perrigo?
Founded in 1887 and currently headquartered in Dublin, Ireland, Perrigo Company operates as a premier global healthcare supplier. The firm specializes in the development and manufacturing of private label over-the-counter pharmaceuticals, providing essential health solutions to a diverse international consumer base. By maintaining a robust supply chain and adhering to rigorous quality standards, Perrigo has established itself as a critical partner for retailers seeking high-quality, cost-effective alternatives to branded medications. Its market position is defined by a unique blend of historical longevity and modern manufacturing agility, allowing it to navigate complex regulatory environments while maintaining consistent product availability across global markets.
How much funding has Perrigo raised?
Perrigo has raised a total of $1B across 1 funding round:
Stock Offering
$1B
Stock Issuance/Offering (2014): $1B, investors not publicly disclosed
Key Investors in Perrigo
Undisclosed Institutional Investor
An undisclosed institutional entity providing significant capital to support large-scale corporate growth and strategic market expansion.
Undisclosed Private Equity Firm
A private equity firm specializing in long-term value creation and the stabilization of legacy healthcare manufacturing assets.
Undisclosed Strategic Partner
A strategic investment group focused on enhancing the operational efficiency and global distribution networks of established pharmaceutical suppliers.
What's next for Perrigo?
With the successful acquisition of this major strategic investment, Perrigo is positioned to accelerate its long-term growth trajectory. The company is expected to leverage this capital to optimize its production infrastructure and potentially pursue strategic acquisitions that align with its core mission of providing affordable healthcare. As the pharmaceutical industry faces increasing pressure for cost transparency and supply chain resilience, Perrigo's focus on private label excellence provides a defensive moat. Future strategic initiatives will likely prioritize digital transformation in manufacturing and the expansion of its portfolio into emerging therapeutic categories, ensuring the company remains at the forefront of the consumer healthcare evolution.
See full Perrigo company page
